Cellect Biotech falls on direct share offering

Quoin Pharmaceuticals

08/01/2020 14:29

** U.S.-listed shares of Cellect Biotechnology Ltd  APOP.O 
down 15% premarket after Israel-based stem cell therapy
developer raises equity
    ** Cellect says sold 1 mln ADSs at $3 to institutional
investors  urn:newsml:reuters.com:*:nPnbJMq2Na
    ** A.G.P./Alliance Global Partners acted as sole placement
agent for offering
    ** APOP shares soared 69.7% to $4.09 on Tues after co said
European Patent Office and Israeli Intellectual Property Office
intend to grant patents for a method of producing stem cells
more quickly  urn:newsml:reuters.com:*:nL4N29C2R1  urn:newsml:reuters.com:*:nPn7vV6D4a
    ** Cellect's stock plunged 79% in 2019, following 70% dive
in 2018
    

 ((lance.tupper.tr.com@reuters.net
lance.tupper@tr.com 646-223-5017))